134 related articles for article (PubMed ID: 16968237)
1. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM; Shuler C
J Oral Pathol Med; 2006 Oct; 35(9):560-7. PubMed ID: 16968237
[TBL] [Abstract][Full Text] [Related]
2. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
3. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
4. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
[TBL] [Abstract][Full Text] [Related]
5. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
[TBL] [Abstract][Full Text] [Related]
6. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
7. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
[TBL] [Abstract][Full Text] [Related]
8. Expression of complement regulatory proteins on human natural killer cell subsets.
Wang L; Halliday D; Johnson PM; Christmas SE
Immunol Lett; 2007 Oct; 112(2):104-9. PubMed ID: 17719652
[TBL] [Abstract][Full Text] [Related]
9. Expression of cancer testis antigens in head and neck squamous cell carcinomas.
Figueiredo DL; Mamede RC; Proto-Siqueira R; Neder L; Silva WA; Zago MA
Head Neck; 2006 Jul; 28(7):614-9. PubMed ID: 16475205
[TBL] [Abstract][Full Text] [Related]
10. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue.
Murray KP; Mathure S; Kaul R; Khan S; Carson LF; Twiggs LB; Martens MG; Kaul A
Gynecol Oncol; 2000 Feb; 76(2):176-82. PubMed ID: 10637067
[TBL] [Abstract][Full Text] [Related]
11. Effect of periodontopathogen lipopolysaccharides and proinflammatory cytokines on CD46, CD55, and CD59 gene/protein expression by oral epithelial cells.
Mahtout H; Curt S; Chandad F; Rouabhia M; Grenier D
FEMS Immunol Med Microbiol; 2011 Aug; 62(3):295-303. PubMed ID: 21545652
[TBL] [Abstract][Full Text] [Related]
12. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.
Shang Y; Chai N; Gu Y; Ding L; Yang Y; Zhou J; Ren G; Hao X; Fan D; Wu K; Nie Y
Arch Pathol Lab Med; 2014 Jul; 138(7):910-9. PubMed ID: 24978917
[TBL] [Abstract][Full Text] [Related]
13. Oncofetal antigen expression in head and neck carcinoma.
Gussack GS
Laryngoscope; 1992 Feb; 102(2):168-76. PubMed ID: 1738289
[TBL] [Abstract][Full Text] [Related]
14. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
15. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
16. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma.
Croce MV; Rabassa ME; Pereyra A; Segal-Eiras A
Head Neck; 2008 May; 30(5):647-57. PubMed ID: 18302268
[TBL] [Abstract][Full Text] [Related]
18. Expression of melanoma-associated antigens in oral squamous cell carcinoma.
Ries J; Vairaktaris E; Mollaoglu N; Wiltfang J; Neukam FW; Nkenke E
J Oral Pathol Med; 2008 Feb; 37(2):88-93. PubMed ID: 18197853
[TBL] [Abstract][Full Text] [Related]
19. Salivary soluble CD44: a potential molecular marker for head and neck cancer.
Franzmann EJ; Reategui EP; Carraway KL; Hamilton KL; Weed DT; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):735-9. PubMed ID: 15767360
[TBL] [Abstract][Full Text] [Related]
20. Comparison of surface HLA class I levels in squamous cell carcinoma cell lines of the head and neck.
Mandic R; Lieder A; Sadowski M; Peldszus R; Werner JA
Anticancer Res; 2004; 24(2B):973-9. PubMed ID: 15161052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
